Pharmacokinetic changes during extracorporeal membrane oxygenation: Implications for drug therapy of neonates

Clinical Pharmacokinetics

Volumn 42, Issue 5, 2003, Pages 403-417

  Buck, Marcia L ^a,b  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALTEPLASE; AMINOCAPROIC ACID; AMINOPHYLLINE; AMPHOTERICIN; AMPICILLIN; BENZODIAZEPINE DERIVATIVE; BUMETANIDE; CEFAZOLIN; CEFOTAXIME; DIAZEPAM; FAMOTIDINE; FENTANYL; FUROSEMIDE; GENTAMICIN; HEPARIN; HYDRALAZINE; LORAZEPAM; MIDAZOLAM; MORPHINE; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; RANITIDINE; RIBAVIRIN; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; EXTRACORPOREAL OXYGENATION; HEMOFILTRATION; HUMAN; KIDNEY FUNCTION; LAMB; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; REVIEW;

ANIMALS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INFANT, NEWBORN; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0038696153     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342050-00001     Document Type: Review

References (49)

1. Somme S, Liu DC. New trends in extracorporeal membrane oxygenation in newborn pulmonary diseases. Artif Organs 2001; 25: 633-7
2. Extracorporeal Life Support Group. Extracorporeal membrane oxygenation registry report. Ann Arbor (MI): Extracorporeal Life Support Organisation; 2002 Jan
3. Rais-Bahrami K, Short BL. The current status of neonatal extracorporeal membrane oxygenation. Semin Perinatol 2000; 24: 406-17
4. Schumacher RE, Baumgart S. Extracorporeal membrane oxygenation 2001: the odyssey continues. Clin Perinatol 2001; 28: 629-53
5. Roy BJ, Rycus P, Conrad SA, et al. The changing demographics of neonatal extracorporeal membrane oxygenation patients reported to the Extracorporeal Life Support Organization (ELSO) registry. Pediatrics 2000; 106: 1334-8
6. Jaggers JJ, Forbess JM, Shah AS, et al. Extracorporeal membrane oxygenation for infant postcardiotomy support: significance of shunt management. Ann Thorac Surg 2000; 69: 1476-83
7. Hopper AO, Pageau J, Job L, et al. Extracorporeal membrane oxygenation for perioperative support in neonatal and pediatric cardiac transplantation. Artif Organs 1999; 23: 1006-9
8. Champion MP, Murdoch IA, Sajjanhar T, et al. Extracorporeal membrane oxygenation for refractory shock in fulminant meningococcal sepsis. Lancet 1996; 347: 201-2
9. Rais-Bahrami K, Short BL. Citrobacter sepsis and severe newborn respiratory failure supported with extracorporeal membrane oxygenation. J Perinatol 2000; 20: 265-6
10. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1989; 33: 817-9
11. Cohen P, Collart L, Prober CG, et al. Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. Pediatr Infect Dis J 1990; 9: 562-6
12. Dodge WF, Jelliffe RW, Zwischenberger JB, et al. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994; 16: 552-9
13. Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1992; 12: 28-32
14. Buck ML. Assessment of gentamicin dosing intervals in neonates receiving extracorporeal membrane oxygenation [abstract]. Pharmacotherapy 1995; 15: 384
15. Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans 1991; 37: 16-8
16. Szefler SJ, Wynn RJ, Clarke DF, et al. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr 1980; 97: 312-5
17. Moller JC, Gilman JT, Kearns GL, et al. Effect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep. Crit Care Med 1992; 20: 1454-8
18. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm 1990; 9: 711-5
19. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996; 40: 1139-42
20. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998; 18: 1082-6
21. Wells TG, Fasules JW, Taylor BJ, et al. Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. J Pediatr 1992; 121: 974-80
22. Wells TG, Heulitt M, Taylor BJ, et al. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol 1998; 38: 402-7
23. Mulla H, Nabi F, Nichani S, et al. Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. Br J Clin Pharmacol 2003; 55: 23-31
24. Sell LL, Cullen ML, Whittlesey GC, et al. Experience with renal failure during extracorporeal membrane oxygenation: treatment with continuous hemofiltration. J Pediatr Surg 1987; 22: 600-2
25. Roy BJ, Cornish JD, Clark RH. Venovenous extracorporeal membrane oxygenation affects renal function. Pediatrics 1995; 95: 573-8
26. Meyer DM, Jessen ME. Results of extracorporeal membrane oxygenation in neonates with sepsis: The Extracorporeal Life Support Organization experience. J Thorac Cardiovasc Surg 1995; 109: 419-25
27. Hoie EB, Hall MC, Schaaf LJ. Effects of injection site and flow rate on the distribution of injected solutions in an extracorporeal membrane oxygenation circuit. Am J Hosp Pharm 1993; 50: 1902-6
28. Dagan O, Klein J, Gruenwald C, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993; 15: 263-6
29. Mulla H, Lawson G, von Anrep C, et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 2000; 15: 21-6
30. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 1999; 23: 979-83
31. Graves DF, Chernin JM, Kurusz M, et al. Anticoagulation practices during neonatal extracorporeal membrane oxygenation: survey results. Perfusion 1996; 11: 461-6
32. Green TP, Isham-Schopf B, Irmiter RJ, et al. Inactivation of heparin during extracorporeal circulation in infants. Clin Pharmacol Ther 1990; 48: 148-54
33. Kawada T, Kitagawa H, Hoson M, et al. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000; 14: 445-57
34. Caron E, Maguire DP. Current management of pain, sedation, and narcotic physical dependency of the infant on ECMO. J Perinat Neonatal Nuts 1990; 4: 63-74
35. Arnold JH, Truog RD, Orav EJ, et al. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anesthesiology 1990; 73: 1136-40
36. Arnold JH, Truog RD, Scavone JM, et al. Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion. J Pediatr 1991; 119: 639-43
37. Burda G, Trittenwein G. Issues of pharmacology in pediatric cardiac extracorporeal membrane oxygenation with special reference to analgesia and sedation. Artif Organs 1999; 23: 1015-9
38. Franck LS, Vilardi J, Durand D, et al. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation. Am J Crit Care 1998; 7: 364-9
39. Geiduschek JM, Lynn AM, Bratton SL, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med 1997; 25: 360-4
40. Dagan O, Klein J, Bohn D, et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med 1994; 22: 1099-101
41. Koren G, Crean P, Klein J, et al. Sequestration of fentanyl by the cardiopulmonary bypass. Eur J Clin Pharmacol 1984; 27: 51-6
42. Hynynen M. Binding of fentanyl and alfentanil to the extracorporeal circuit. Acta Anaesthesiol Scand 1987; 31: 706-10
43. Leuschen MP, Willett LD, Hoie EB, et al. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 1993; 105: 885-91
44. Scala JL, Jew RK, Pooh CY, et al. In vitro analysis of furosemide disposition during neonatal extracorporeal membrane oxygenation (ECMO) [abstract]. Pediatr Res 1996; 39: 78A
45. Marx CM, Litmanovitz I, Ksenich R, et al. Investigation of increased phenobarbital dose requirements for newborn infants on ECMO: in vitro adsorption to ECMO circuit [abstract]. Pharmacotherapy 1991; 11: 270
46. Elliott ESR, Buck ML. Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother 1999; 33: 419-22
47. Kroh UF, Holl T, Fueussner KD. Pharmacokinetics and dosage adjustment of antibiotics during continuous extracorporeal lung assistance and hemofiltration. Artif Organs 1992; 16: 457-60
48. Aebi C, Headrick CL, McCracken GH, et al. Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration. J Pediatr 1997; 130: 612-5
49. Lindsay CA, Bawdon R, Quigley R. Clearance of ticarcillin-clavulanic acid by continuous venovenous hemofiltration in three critically ill children, two with and one without concomitant extracorporeal membrane oxygenation. Pharmacotherapy 1996; 16: 458-62